Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an EBITDA of NOK 10.2 million (Q3 2024: NOK 5.0 ...
TipRanks on MSN
Photocure ASA Reports Strong Q3 2025 Growth
Photocure ASA ( ($PHCUF) ) has released its Q3 earnings. Here is a breakdown of the information Photocure ASA presented to its investors.
13d
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the ...
Merck (MRK) stock is in focus as the company's Keytruda versions win FDA priority review for an expanded indication in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback